Acasti Pharma, Inc. - (ACST): Price and Financial Metrics

Acasti Pharma, Inc. - (ACST): $3.41

0.01 (+0.29%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add ACST to Watchlist
Sign Up

ACST Price/Volume Stats

Current price $3.41 52-week high $3.84
Prev. close $3.40 52-week low $1.72
Day low $3.31 Volume 5,800
Day high $3.42 Avg. volume 27,858
50-day MA $3.19 Dividend yield N/A
200-day MA $2.61 Market Cap 32.05M

ACST Stock Price Chart Interactive Chart >


Acasti Pharma, Inc. - (ACST) Company Bio


Acasti Pharma Inc operates as pharmaceutical company. The Company develops drugs for cardiovascular diseases. Acasti offers omega-3 phospholipids a major component of cell membranes.


ACST Latest News Stream


Event/Time News Detail
Loading, please wait...

ACST Latest Social Stream


Loading social stream, please wait...

View Full ACST Social Stream

Latest ACST News From Around the Web

Below are the latest news stories about ACASTI PHARMA INC that investors may wish to consider to help them evaluate ACST as an investment opportunity.

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | December 25, 2023

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024

PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel intravenous formulation of nimodipine being developed to address the high unmet medical needs for a rare disease, aneurysmal Subarachnoid Hemorrhage (aSAH), today announced that Chief Executive Officer Prashant Kohli will participate in the following investor and industry networking events in San Francisco, California during th

Yahoo | December 13, 2023

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Announced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104 Completed $7.5 Million Private Placement Equity Financing led by ADAR1 Partners, LP, Providing Funding Well Beyond Anticipated Submission of GTX-104 New Drug Application (NDA) Highlighted the Potential of GTX-104 as New Treatment Standard for Aneurysmal Subarachnoid Hemorrhage (aSAH) in Key Opinion Leader Virtual WebinarPresented Poster on Pharmacokinetic Comparison of GTX-104 with Oral Nimodipine at 2023

Yahoo | November 13, 2023

Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial

With achievement of enrollment milestone, pivotal STRIVE-ON safety trial on track for potential NDA submission anticipated to occur in the first half of calendar 2025 Recently announced $7.5 million private placement financing extends projected cash runway to the first calendar quarter of 2026 PRINCETON, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that add

Yahoo | October 23, 2023

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

Virtual Webinar to Take Place October 11, 2023 at 2:00pm ETPRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that it will host a virtual KOL event titled GTX-104: a potential new treatment standard for rare and life-threatening aS

Yahoo | October 4, 2023

Read More 'ACST' Stories Here

ACST Price Returns

1-mo 0.00%
3-mo 27.24%
6-mo 27.24%
1-year 20.97%
3-year -84.80%
5-year -92.52%
YTD 17.99%
2023 -3.86%
2022 -60.24%
2021 -51.54%
2020 -86.73%
2019 195.18%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!